` ACIU (AC Immune SA) vs S&P 500 Comparison - Alpha Spread

ACIU
vs
S&P 500

Over the past 12 months, ACIU has underperformed S&P 500, delivering a return of -46% compared to the S&P 500's 12% growth.

Stocks Performance
ACIU vs S&P 500

Loading

Performance Gap
ACIU vs S&P 500

Loading
ACIU
S&P 500
Difference

Performance By Year
ACIU vs S&P 500

Loading
ACIU
S&P 500
Add Stock

Competitors Performance
AC Immune SA vs Peers

S&P 500
ACIU
ABBV
AMGN
GILD
VRTX
Add Stock

AC Immune SA
Glance View

Market Cap
171.7m USD
Industry
Biotechnology

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

ACIU Intrinsic Value
7.51 USD
Undervaluation 77%
Intrinsic Value
Price
Back to Top